Carboplatin (Page 3 of 6)

ADVERSE REACTIONS:

For a comparison of toxicities when carboplatin or cisplatin was given in combination with cyclophosphamide, see CLINICAL STUDIES, Use with Cyclophosphamide for Initial Treatment of Ovarian Cancer, Comparative Toxicity.

.

ADVERSE EXPERIENCES IN PATIENTS WITH OVARIAN CANCER
First Line Combination Therapy * Percent Second Line Single Agent Therapy ** Percent
Bone Marrow
Thrombocytopenia
< 100,000/mm 3 66 62
< 50,000/mm 3 33 35
Neutropenia
< 2,000 cells/mm 3 96 67
< 1,000 cells/mm 3 82 21
Leukopenia
< 4,000 cells/mm 3 97 85
< 2,000 cells/mm 3 71 26
Anemia
< 11/g/dL 90 90
< 8 g/dL 14 21
Infections 16 5
Bleeding 8 5
Transfusions 35 44
Gastrointestinal
Nausea and vomiting 93 92
Vomiting 83 81
Other GI side effects 46 21
Neurologic
Peripheral neuropathies 15 6
Ototoxicity 12 1
Other sensory side effects 5 1
Central neurotoxicity 26 5
Renal
Serum creatinine elevations 6 10
Blood urea elevations 17 22
Hepatic
Bilirubin elevations 5 5
SGOT elevations 20 19
Alkaline phosphatase elevations 29 37
Electrolytes loss
Sodium 10 47
Potassium 16 28
Calcium 16 31
Magnesium 61 43
Other side effects
Pain 44 23
Asthenia 41 11
Cardiovascular 19 6
Respiratory 10 6
Allergic 11 2
Genitourinary 10 2
Alopecia 49 2
Mucositis 8 1

*Use with Cyclophosphamide for Initial
Treatment of Ovarian Cancer

Data are based on the experience of 393 patients with ovarian cancer (regardless of baseline status) who received initial combination therapy with carboplatin and cyclophosphamide in two randomized controlled studies conducted by SWOG and NCIC (see CLINICAL STUDIES).

Combination with cyclophosphamide as well as duration of treatment may be responsible for the differences that can be noted in the adverse experience table.

**Single Agent Use for the Secondary Treatment of Ovarian Cancer

Data are based on the experience of 553 patients with previously treated ovarian carcinoma (regardless of baseline status) who received single-agent carboplatin.

In the narrative section that follows, the incidences of adverse events are based on data from 1,893 patients with various types of tumors who received carboplatin as single-agent therapy.

All MedLibrary.org resources are included in as near-original form as possible, meaning that the information from the original provider has been rendered here with only typographical or stylistic modifications and not with any substantive alterations of content, meaning or intent.

This site is provided for educational and informational purposes only, in accordance with our Terms of Use, and is not intended as a substitute for the advice of a medical doctor, nurse, nurse practitioner or other qualified health professional.

Privacy Policy | Copyright © 2021. All Rights Reserved.